Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$5.58 USD
0.00 (0.00%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $5.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum B VGM
Brokerage Reports
Oncobiologics, Inc. [OTLK]
Reports for Purchase
Showing records 1 - 20 ( 41 total )
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
BLA Submission Now Expected In CY1Q25; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
EU And UK Launch Expected In 1Q25; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
First Subject of NORSE EIGHT Dosed, Setting Up Readout and BLA Resubmission Before Year-End
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Cleaning Up the Blocks Towards Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Study Design Brings No Surprises As Path Forward Looks Clear; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
The Most Clarity We''ve Ever Had on ONS-5010''s Development; Upgrade to Buy; PT Up to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Lytenava Receives a CRL and We Move to the Sidelines: Downgrade to Neutral; Lower PT to $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Perspectives on the Cost-Effectiveness of Treating wet AMD
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Outlook Therapeutic''s F2Q23 in Numbers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from our Conversation with Outlook Therapeutics? Management; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Outlook Therapeutic''s F2Q23 in Numbers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Pre-Launch Activities for Lytenava at Full Steam; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Time to Build Up Commercial Capabilities; PT Down to $5; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
BLA Resubmission Marks Progress Towards Commercialization
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Looks Like a Fast Turnaround for BLA Resubmission; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Time to Start Looking Towards Commercialization; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Lytenava BLA Filing Imminent and Plenty to Look Forward to in Next Two Years; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Rx for Portfolios, Part 2: Companies With Significant Upcoming Regulatory Decisions
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D